Compounds > soyasapogenol a
Page last updated: 2024-12-08

soyasapogenol a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

soyasapogenol A: RN refers to (3beta,4beta,21beta,22beta)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

soyasapogenol A : A pentacyclic triterpenoid that is oleanane containing a double bond between positions 12 and 13 and substituted by hydroxy groups at the 3beta, 21beta, 22beta and 24-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12442849
CHEMBL ID1762006
CHEBI ID62440
SCHEMBL ID828826
MeSH IDM0299706

Synonyms (21)

Synonym
soyasapogenol a
C17419
508-01-0
CHEBI:62440 ,
CHEMBL1762006
(3beta,4beta,21beta,22beta)-olean-12-ene-3,21,22,23-tetrol
3beta,21beta,22beta,24-tetrahydroxyolean-12-ene
soyasapogenol-a
(3beta,21beta,22beta)-olean-12-ene-3,21,22,24-tetrol
unii-43t6j3o9wl
olean-12-ene-3,21,22,23-tetrol, (3beta,4beta,21beta,22beta)-
43t6j3o9wl ,
olean-12-ene-3.beta.,21.beta.,22.beta.,24-tetrol
olean-12-ene-3,21,22,23-tetrol, (3.beta.,4.beta.,21.beta.,22.beta.)-
SCHEMBL828826
soyasapogenol a(p)
AKOS032945989
Q27131898
CS-0032501
HY-N6073
MS-28813

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The bioavailability and absorption of soyasaponins and soyasapogenols remain unclear; therefore, the aim of this study was to evaluate plasma soyasaponin and soyasapogenol concentrations and absorption characteristics."( Comparison of bioavailability (I) between soyasaponins and soyasapogenols, and (II) between group A and B soyasaponins.
Kamo, S; Sato, T; Suzuki, S, 2014)		0.4
"These results suggest that bioavailability of soyasapogenols is better than that of corresponding soyasaponins and that of group B soyasaponins is better than that of group A soyasaponins."( Comparison of bioavailability (I) between soyasaponins and soyasapogenols, and (II) between group A and B soyasaponins.
Kamo, S; Sato, T; Suzuki, S, 2014)		0.4
"Research suggests that soyasaponins are poorly absorbed in the GI tract and that soyasaponin aglycones or soyasapogenols are absorbed faster and in greater amounts than the corresponding soyasaponins."( The Fate and Intermediary Metabolism of Soyasapogenol in the Rat.
Pan, C; Yan, Y; Zhao, D, 2022)		0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pentacyclic triterpenoid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID589618Inhibition of iNOS activity in LPS-stimulated mouse RAW264.7 cells assessed as conversion of L-[14H] arginine to L-[3H] citruline per mg of protein at 50 ug/ml after 24 hrs2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID589616Inhibition of iNOS activity in LPS-stimulated mouse RAW264.7 cells assessed as conversion of L-[14H] arginine to L-[3H] citruline per mg of protein at 200 ug/ml after 24 hrs2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID589628Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW264.7 cells at 25 to 200 ug/ml measured after 24 hrs by Griess reaction method2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID589619Inhibition of iNOS activity in LPS-stimulated mouse RAW264.7 cells assessed as conversion of L-[14H] arginine to L-[3H] citruline per mg of protein at 25 ug/ml after 24 hrs2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID589622Inhibition of iNOS mRNA expression in LPS-stimulated mouse RAW264.7 cells at 100 ug/ml after 24 hrs by real time fluorescent quantitative real time PCR relative to negative control2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID589617Inhibition of iNOS activity in LPS-stimulated mouse RAW264.7 cells assessed as conversion of L-[14H] arginine to L-[3H] citruline per mg of protein at 100 ug/ml after 24 hrs2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID589530Cytotoxicity against mouse RAW264.7 cells at 25 to 200 ug/ml after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID589624Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha release by ELISA2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID1831041Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of HMGB1-induced NO production pretreated with compounds for 15 mins followed by HMGB1 stimulation measured after 24 hrs by Griess reagent based assay2021Bioorganic & medicinal chemistry, 12-15, Volume: 52Microbial transformation of pentacyclic triterpenes for anti-inflammatory agents on the HMGB1 stimulated RAW 264.7 cells by Streptomyces olivaceus CICC 23628.
AID589621Inhibition of iNOS mRNA expression in LPS-stimulated mouse RAW264.7 cells at 50 ug/ml after 24 hrs by real time fluorescent quantitative real time PCR relative to negative control2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID589625Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 release by ELISA2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID589623Inhibition of iNOS mRNA expression in LPS-stimulated mouse RAW264.7 cells at 200 ug/ml after 24 hrs by real time fluorescent quantitative real time PCR relative to negative control2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID589620Inhibition of iNOS mRNA expression in LPS-stimulated mouse RAW264.7 cells at 25 ug/ml after 24 hrs by real time fluorescent quantitative real time PCR relative to negative control2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
AID86198Hepatoprotective activity against aflatoxin B1 (10e-5 M) induced Hep G2 cells at a dose of 10 ug/ml1998Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6
Derivatization of soyasapogenol A and their hepatoprotective activities.
AID589626Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1 release by ELISA2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (4.76)18.2507
2000's9 (42.86)29.6817
2010's8 (38.10)24.3611
2020's3 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pimagedine
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.		2.0610guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor
oleanolic acid
[no description available]		4.4200hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
glycyrrhizic acid
glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.		1.9910enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
tocopherols
[no description available]		2.4920
uridine diphosphate glucuronic acid
Uridine Diphosphate Glucuronic Acid: A nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis. It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones.. UDP-alpha-D-glucuronic acid : A UDP-sugar having alpha-D-glucuronic acid as the sugar component.		2.0110UDP-D-glucuronic acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
betulinic acid
[no description available]		2.3110hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
beta-amyrin
beta-amyrin: alpha-amyrin is also available; a 5 ring triterpene derived from oleanane that differs from alpha-amyrin in having the 29-carbon at the 20 position; RN given refers to (3 beta)-isomer. beta-amyrin : A pentacyclic triterpenoid that is oleanane substituted at the 3beta-position by a hydroxy group and containing a double bond between positions 12 and 13. It is one of the most commonly occurring triterpenoids in higher plants.		2.1510pentacyclic triterpenoid;
secondary alcohol		Aspergillus metabolite;
plant metabolite
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		2.011017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
soyasapogenol b
soyasapogenol B: RN given for (3beta,4beta,22beta)-isomer; structure in first source. soyasapogenol B : A pentacyclic triterpenoid that is oleanane containing a double bond between positions 12 and 13 and substituted by hydroxy groups at the 3beta, 22beta and 24-positions.		8.92120pentacyclic triterpenoid
soyasaponin bb
soyasaponin Bb: has activity against polycystic kidney disease; isolated from soybean; structure in first source. soyasaponin I : A triterpenoid saponin that is composed of soyasapogenol B having an alpha-L-rhamnopyranosyl-(1->2)-beta-D-galactopyranosyl-(1->2)-beta-D-glucopyranosiduronic acid moiety attached at the 3-position via a glycosidic linkage.		2.7730carbohydrate acid derivative;
pentacyclic triterpenoid;
trisaccharide derivative;
triterpenoid saponin		sialyltransferase inhibitor
soyasaponin ii
soyasaponin II: isolated from the soybean Glycine max; RN given for (3beta,4beta,22beta)-isomer		2.0210triterpenoid saponin
carbenoxolone
[no description available]		2.3110
beta-escin
[no description available]		3.99130
me3738
ME3738: structure in first source		2.0110
phytoestrogens
Phytoestrogens: Compounds derived from plants, primarily ISOFLAVONES that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS.		2.0110
soyasaponin iii
soyasaponin III: from Medicago hispida; structure given in first source. soyasaponin III : A triterpenoid saponin that is composed of soyasapogenol B having a beta-D-galactopyranosyl-(1->2)-beta-D-glucopyranosiduronic acid moiety attached at the 3-position via a glycosidic linkage.		2.4220
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		7.4120
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Lung
[description not available]		02.2510
Invasiveness, Neoplasm
[description not available]		02.2510
Lung Neoplasms
Tumors or cancer of the LUNG.		02.2510
Polyarthritis
[description not available]		02.1710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1710
Innate Inflammatory Response
[description not available]		02.1710
Arthritis
Acute or chronic inflammation of JOINTS.		02.1710
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1710
Breast Cancer
[description not available]		02.0110
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0110
Acute-Phase Reaction
An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma.		02.0110
Hepatic Failure
[description not available]		02.0110
Liver Failure
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)		02.0110
Cancer of Colon
[description not available]		02.0110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0110
Hepatocellular Carcinoma
[description not available]		02.0410
Cancer of Liver
[description not available]		02.0410
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.0410
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0410
Hepatitis, Animal
INFLAMMATION of the LIVER in non-human animals.		0210